Literature DB >> 8095167

Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RAR alpha present in acute promyelocytic leukemia cells.

C Gambacorti-Passerini1, F Grignani, F Arienti, P P Pandolfi, P G Pelicci, G Parmiani.   

Abstract

Fusion proteins present in leukemic cells frequently contain a new amino acid at the fusion point. We tested whether a peptide (BCR1/25) encompassing the fusion region of the hybrid molecule pml/RAR alpha, which is selectively expressed by acute promyelocytic leukemia (APL) cells, can be recognized by human T lymphocytes in vitro. CD4+ lymphocytes, at both polyclonal and clonal level, recognized peptide BCR1/25 in an HLA-DR--restricted fashion on presentation by autologous antigen-presenting cell (APC) or by APC expressing the HLA-DR11 restricting molecule. Control peptides corresponding to the normal pml and RAR alpha proteins were not recognized. One clone (DEG5) also exerted a high and specific cytotoxicity against autologous cells pulsed with BCR1/25. The autologous DE LCL containing a transduced pml/RAR alpha fusion gene and expressing a bcr1 type of the pml/RAR alpha hybrid protein induced the proliferation of DE anti-BCR1/25 T cell clones. It is concluded that the bcr1 type-pml/RAR alpha fusion protein of APL contains an antigenic site, absent from the normal parent molecules and recognized by human CD4+ lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8095167

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  23 in total

Review 1.  Personal tumor antigens in blood malignancies: genomics-directed identification and targeting.

Authors:  Livius Penter; Catherine J Wu
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

Review 2.  Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy.

Authors:  Pierre G Coulie; Benoît J Van den Eynde; Pierre van der Bruggen; Thierry Boon
Journal:  Nat Rev Cancer       Date:  2014-02       Impact factor: 60.716

Review 3.  Tumor cells engineered to produce cytokines or cofactors as cellular vaccines: do animal studies really support clinical trials?

Authors:  M P Colombo; M Rodolfo
Journal:  Cancer Immunol Immunother       Date:  1995-11       Impact factor: 6.968

Review 4.  Translational mini-review series on vaccines: Peptide vaccines for myeloid leukaemias.

Authors:  A J Barrett; K Rezvani
Journal:  Clin Exp Immunol       Date:  2007-05       Impact factor: 4.330

Review 5.  Immunotherapy for myeloid leukemias: current status and future directions.

Authors:  K el-Shami; B D Smith
Journal:  Leukemia       Date:  2008-06-19       Impact factor: 11.528

Review 6.  Immunological weapons against acute myeloid leukaemia.

Authors:  Joanna Galea-Lauri
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

7.  Adaptive immunity cooperates with liposomal all-trans-retinoic acid (ATRA) to facilitate long-term molecular remissions in mice with acute promyelocytic leukemia.

Authors:  Peter Westervelt; Jessica L Pollock; Kristie M Oldfather; Matthew J Walter; Margaret K Ma; Anthony Williams; John F DiPersio; Timothy J Ley
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-20       Impact factor: 11.205

Review 8.  Immunotherapy in acute leukemia.

Authors:  Wing Leung
Journal:  Semin Hematol       Date:  2009-01       Impact factor: 3.851

9.  Hematopoietic stem cell transplant for pediatric acute promyelocytic leukemia.

Authors:  Christopher C Dvorak; Rajni Agarwal; Gary V Dahl; John J Gregory; James H Feusner
Journal:  Biol Blood Marrow Transplant       Date:  2008-07       Impact factor: 5.742

Review 10.  The role of the immune system in anti-tumour responses. Potential for drug therapy.

Authors:  S Dermime; J Barrett; C Gambacorti-Passerini
Journal:  Drugs Aging       Date:  1995-10       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.